These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 30552865)

  • 1. Ki-67 labeling index in glioblastoma; does it really matter?
    Alkhaibary A; Alassiri AH; AlSufiani F; Alharbi MA
    Hematol Oncol Stem Cell Ther; 2019 Jun; 12(2):82-88. PubMed ID: 30552865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic relevance of NG2/CSPG4, CD44 and Ki-67 in patients with glioblastoma.
    Tsidulko AY; Kazanskaya GM; Kostromskaya DV; Aidagulova SV; Kiselev RS; Volkov AM; Kobozev VV; Gaitan AS; Krivoshapkin AL; Grigorieva EV
    Tumour Biol; 2017 Sep; 39(9):1010428317724282. PubMed ID: 28945172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cut-point for Ki-67 proliferation index as a prognostic marker for glioblastoma.
    Wong E; Nahar N; Hau E; Varikatt W; Gebski V; Ng T; Jayamohan J; Sundaresan P
    Asia Pac J Clin Oncol; 2019 Feb; 15(1):5-9. PubMed ID: 29336530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of proliferation index on outcome in childhood malignant gliomas: results in a multi-institutional cohort.
    Pollack IF; Hamilton RL; Burnham J; Holmes EJ; Finkelstein SD; Sposto R; Yates AJ; Boyett JM; Finlay JL
    Neurosurgery; 2002 Jun; 50(6):1238-44; discussion 1244-5. PubMed ID: 12015841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perfusion Parameter Obtained on 3-Tesla Magnetic Resonance Imaging and the Ki-67 Labeling Index Predict the Overall Survival of Glioblastoma.
    Fudaba H; Momii Y; Matsuta H; Onishi K; Kawasaki Y; Sugita K; Shimomura T; Fujiki M
    World Neurosurg; 2021 May; 149():e469-e480. PubMed ID: 33567368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different assessments of immunohistochemically stained Ki-67 and hTERT in glioblastoma multiforme yield variable results: a study with reference to survival prognosis.
    Persson A; Englund E
    Clin Neuropathol; 2008; 27(4):224-33. PubMed ID: 18666438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Multifocality and Molecular Markers on Survival of Glioblastoma.
    Ahmadipour Y; Jabbarli R; Gembruch O; Pierscianek D; Darkwah Oppong M; Dammann P; Wrede K; Özkan N; Müller O; Sure U; El Hindy N
    World Neurosurg; 2019 Feb; 122():e461-e466. PubMed ID: 30347300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of Ki-67, topoisomerase IIalpha and c-MYC in astrocytic tumors: correlation with the histopathological grade and proliferative status.
    Faria MH; Gonçalves BP; do Patrocínio RM; de Moraes-Filho MO; Rabenhorst SH
    Neuropathology; 2006 Dec; 26(6):519-27. PubMed ID: 17203587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is Ki-67 index overexpression in IDH wild type glioblastoma a predictor of shorter Progression Free survival? A clinical and Molecular analytic investigation.
    Armocida D; Frati A; Salvati M; Santoro A; Pesce A
    Clin Neurol Neurosurg; 2020 Nov; 198():106126. PubMed ID: 32861131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between Ki-67 Labeling index and Histopathological Grading of Glioma in Indonesian Population.
    Theresia E; Malueka RG; Pranacipta S; Kameswari B; Dananjoyo K; Asmedi A; Wicaksono AS; Hartanto RA; Dwianingsih EK
    Asian Pac J Cancer Prev; 2020 Apr; 21(4):1063-1068. PubMed ID: 32334471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ki-67 Proliferative Activity in the Tumor Margins as a Robust Prognosis Factor in Glioblastoma Patients.
    Tejada S; Becerra-Castro MV; Nuñez-Cordoba J; Díez-Valle R
    J Neurol Surg A Cent Eur Neurosurg; 2021 Jan; 82(1):53-58. PubMed ID: 33260244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic relevance of p53 protein expression in glioblastoma.
    Birner P; Piribauer M; Fischer I; Gatterbauer B; Marosi C; Ungersböck K; Rössler K; Budka H; Hainfellner JA
    Oncol Rep; 2002; 9(4):703-7. PubMed ID: 12066196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between Ki-67 labeling index and survival in high-grade glioma patients treated after surgery with tamoxifen.
    Mastronardi L; Guiducci A; Puzzilli F; Ruggeri A
    J Neurosurg Sci; 1999 Dec; 43(4):263-70. PubMed ID: 10864388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The expression of mismatch repair proteins MLH1, MSH2 and MSH6 correlates with the Ki67 proliferation index and survival in patients with recurrent glioblastoma.
    Stark AM; Doukas A; Hugo HH; Mehdorn HM
    Neurol Res; 2010 Oct; 32(8):816-20. PubMed ID: 20223108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of Ki-67 Index with Volumetric Segmentation and its Value as a Prognostic Marker in Glioblastoma.
    Henker C; Kriesen T; Schneider B; Glass Ä; Scherer M; Langner S; Erbersdobler A; Piek J
    World Neurosurg; 2019 May; 125():e1093-e1103. PubMed ID: 30790732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High expression of DNA topoisomerase IIalpha and Ki-67 antigen is associated with prolonged survival in glioblastoma patients.
    Bredel M; Piribauer M; Marosi C; Birner P; Gatterbauer B; Fischer I; Ströbel T; Rössler K; Budka H; Hainfellner JA
    Eur J Cancer; 2002 Jul; 38(10):1343-7. PubMed ID: 12091064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical analysis of metallothionein in astrocytic tumors in relation to tumor grade, proliferative potential, and survival.
    Hiura T; Khalid H; Yamashita H; Tokunaga Y; Yasunaga A; Shibata S
    Cancer; 1998 Dec; 83(11):2361-9. PubMed ID: 9840536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ki-67 labeling is correlated with the time to recurrence in primary glioblastomas.
    Schröder R; Feisel KD; Ernestus RI
    J Neurooncol; 2002 Jan; 56(2):127-32. PubMed ID: 11995813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative investigation of nuclear morphology in glioblastomas and its relation to survival time.
    Nafe R; Franz K; Schlote W; Schneider B
    Clin Neuropathol; 2003; 22(3):129-36. PubMed ID: 12809355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.